This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.
Upon completion of this activity, participants should be better able to:
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources